# Anlotinib Combined With STUPP for MGMT Nonmethylated Glioblastoma

> **NCT04725214** · PHASE2 · UNKNOWN · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 33 (estimated)

## Conditions studied

- MGMT-Unmethylated Glioblastoma

## Interventions

- **DRUG:** Anlotinib

## Key facts

- **NCT ID:** NCT04725214
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-15
- **Primary completion:** 2022-12
- **Final completion:** 2023-12
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2021-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04725214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04725214, "Anlotinib Combined With STUPP for MGMT Nonmethylated Glioblastoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04725214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*